Project Grant R01DA062689

Award Date 7/15/25
Completion Date 3/31/30
Dollars Obligated $635K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Maryland, EE. UU.
Similar Awards
This Project Grant award of $1,838,237, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the neuronal circuits through which chronic stress promotes habit formation. The award, effective September 15, 2024 and ending May 31, 2029, will be executed by the University of California, Los Angeles (UCLA). The research aims to expose how opposing amygdala-striatal pathways in the brain enable...
This federal Project Grant award of $125,879 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research by Harvard Medical School to investigate how hunger and hypothalamic neurons modulate exploratory behavior and dopaminergic neural activity in mice. The project aims to elucidate the neural pathways by which hunger alters exploratory behavior and provide new insights into the underlying circuitry. Specifically, the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support a $2,075,613 research project conducted by the Regents of the University of Michigan. The project aims to validate a human sign-/goal-tracking paradigm and identify neurobehavioral signatures of sign- and goal-tracking behaviors in emerging adults, which are key to understanding individual differences in addiction liability. The...
This federal Project Grant award of $811,112 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research by the University of California, San Francisco (UCSF) to investigate the brain networks and neural signaling mechanisms that underlie sudden "insight" learning of cue-reward associations. The key objectives are to use advanced techniques like two-photon calcium imaging, high-density...
This $2,419,326 Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a longitudinal study to investigate neurobehavioral and psychosocial predictors of health risk behaviors (HRBs) in adolescence and young adulthood. The primary awardee, Virginia Polytechnic Institute & State University, will conduct assessments over 15 years to understand brain development and its impact on substance use and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is focused on validating a novel computational neurobiological model of costly drug-taking behavior centered on the striosomes of the dorsomedial striatum. The $1,766,868 award to the University of Texas at El Paso will use electrophysiology, optogenetics, and advanced modeling techniques to investigate the role of the prelimbic-striosomal and...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $148,568 to investigate the mechanisms of dopamine transmission and its role in reward-related behaviors. The award period runs from January 1, 2025 to July 31, 2027. The funded research aims to advance the mechanistic understanding of how dopamine signaling occurs at the subcellular level, given limitations in prior methodologies. The...
This $284,040 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to conduct integrated single-cell and spatial mapping of the habenula circuitry to identify projection-specific molecular pathways associated with opioid exposure. The Lieber Institute for Brain Development in Baltimore, MD will lead this research effort from September 1, 2024 to August 31, 2026. The project will generate a...
This federal Project Grant award, with ID R01DA065418, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $390,687 grant will support research at New York University (NYU) to characterize how the orbitofrontal cortex, dorsal striatum, and basolateral amygdala interact to support belief updating and context-dependent decision making, which is relevant for understanding substance use disorders. The research will involve...
This Project Grant award, valued at $136,929.00, was provided by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research at Vanderbilt University to investigate the circuit mechanisms underlying inflexible habitual behaviors following chronic cocaine use. Specifically, the research aims to: 1) Determine if a history of cocaine self-administration alters dopamine release to promote habitual behavior, 2)...

This federal Project Grant award for $634,617, awarded by the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs, will support research on the neural basis of the transition from goal-directed to habitual behavior. The primary objectives are to: 1) validate a novel "volitional engagement" behavioral paradigm using techniques like optogenetics and outcome devaluation, 2) monitor and manipulate neural circuits in the dorsomedial/dorsolateral striatum and premotor cortex to understand the dynamics of habit formation, and 3) extend the behavioral approach to a habit-promoting task in rats. This research aims to provide real-time insights into the neural mechanisms underlying the shift from flexible, goal-directed to automatic, habitual control of behavior, with implications for understanding and potentially treating substance use disorders. The award was made to The Johns Hopkins University, a leading federal contractor and grantee known for its expertise in biomedical research, on Jul 15, 2025, with a project period ending on Mar 31, 2030.

Generated 8/5/25, 5:58 AM